|
Mar 12
|
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
|
|
Mar 11
|
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
|
|
Mar 6
|
Q4 2023 Nuwellis Inc Earnings Call
|
|
Jan 11
|
SeaStar Medical Appoints David A. Green as Chief Financial Officer
|
|
Jan 9
|
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
|
|
Dec 28
|
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
|
|
Aug 22
|
SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time
|